Elsevier

Gynecologic Oncology

Volume 89, Issue 1, April 2003, Pages 140-147
Gynecologic Oncology

Regular article
Expression of p27, p21, and p16 protein in early squamous cervical cancer and its relation to prognosis

https://doi.org/10.1016/S0090-8258(03)00010-6Get rights and content

Abstract

Objectives

To examine the prognostic significance of the protein expression of the cyclin-dependent kinase (cdk) inhibitors p27, p21, and p16 in early squamous cervical cancer (SCC).

Methods

From 212 patients who underwent radical hysterectomy and bilateral lymphadenectomy at our institution for stage IB SCC between 1987 and 1993, tissue blocks were available for this study. Immunohistochemistry using monoclonal antibodies against p27, p21, and p16 was used to examine protein expression. Ten patients who underwent hysterectomy for uterine prolaps served as controls.

Results

p21 and p16 expression were increased in SCC and high expression was observed in 20% (44/221) and 43% (94/220) of tumors, respectively. p27 was decreased in SCC and low expression was found in 80% (177/221) of tumors. In univariate analysis all classical clinicopathological parameters were associated with prognosis. Low p16 expression was significantly related to decreased overall (P = 0.036) but not disease-free survival (P = 0.103). In multivariate analysis, deep stromal invasion but none of the cdk inhibitors was independently related to survival.

Conclusion

The cdk inhibitors p27, p21, and p16 are not independently associated with prognosis in stage IB SCC.

Introduction

Stage I cervical carcinoma has a relatively favorable prognosis with a 5-year survival rate of 80% [1]. Adjuvant treatment, given to about one-third of patients primarily treated with surgery [1], is accompanied by considerable morbidity [2]. Since nearly half of patients present with stage I disease this represents a large group. Knowledge of prognostic factors could help tailor treatment so that overtreatment can be avoided in low risk groups and adjuvant treatment only be given to patients with a high risk of relapse. Pelvic lymph node metastasis, tumor diameter, deep stromal invasion, vascular invasion, and close resection margins have most frequently been identified as prognostic factors [3], [4], [5], [6]. Biomolecular factors could possibly improve this prediction of prognosis and because of their role in tumorigenesis lead to development of new treatment strategies.

The cell cycle is the coordinated sequence of events involved in cell replication. In general, progression through the cell cycle is governed by protein complexes composed of a cyclin and a cyclin-dependent kinase (cdk). The cyclin/cdk complexes drive the cell forward by phosphorylating the retinoblastoma protein (RB). In its active, hypophosphorylated form RB is bound to transcription factors of the E2F family. Upon phosphorylation, these factors are released, leading to transcription of genes responsible for S phase progression. Cdks are opposed by cdk inhibitors. These can be divided in two structurally related families: the Cip/Kip family (p21, p27, and p57), which preferentially inhibits cdk2-containing complexes (cyclin A/E–cdk2) and the INK4 family (p15, p16, p18, and p19), which inhibits cyclin D-containing complexes (cyclin D–cdk4/6). Through their role in the cell cycle, cdk inhibitors can be seen as tumor suppressors and loss of their function could lead to malignant transformation.

p27 is strongly expressed in nonproliferating cells and its primary function seems therefore to be control of proliferation as evidenced by the deregulated growth in p27 knock-out mice [7]. Expression is increased by growth inhibiting signals such as transforming growth factor β (TGF-β)[8] or contact inhibition [9], leading to cell cycle arrest, whereas it is decreased by growth stimulating signals leading to cell cycle progression [10]. p27 thus has a pivotal role in regulating the response of cells to extracellular signals, a rather unique feature among cdk inhibitors. p27 has also been implicated as a mediator in cell differentiation, cell–cell adhesion, and apoptosis (for review, see [11]). The main regulation of the p27 level is thought to be posttranslational through degradation by the ubiquitin–proteasome pathway [12], which was found increased in several human tumors [13]. The human papillomavirus (HPV)-16 E7 oncogene can bind and inactivate p27 without degrading it [14] but this inactivation may not be involved in oncogenic transformation [15].

p21 is often reduced or absent in quiescent cells and it may be primarily involved in controlling cdk activity in proliferating cells [16]. It also plays a role in the response of cells to DNA damage by arresting the cell cycle and enabling repair or, failing this, by triggering apoptosis. In this context p21 is regarded as a major effector of p53 as the p21 gene is under transcriptional control of p53 [17]. However, p21 can be induced in a p53-independent manner [18] and p21 is not required for p53-dependent apoptosis [19]. p21 also binds the proliferating cell nuclear antigen (PCNA), thereby inhibiting replicative DNA synthesis [20]. Through its role in apoptosis and DNA repair p21 could be an important modulator of resistance to chemotherapy and radiation and high levels seem to induce growth arrest and prevent apoptosis [21], [22]. p21 also mediates terminal differentiation in multiple cell types, including keratinocytes [23], and is involved in cell senescence [24]. The HPV-16 E7 oncogene can bind and inactivate p21 without degrading it. This results in high cdk2 activity despite high levels of p21, a situation analogous to that of p27 [25].

p16 is an element of the p16\ cyclinD–cdk4/6 \RB pathway [16]. Disruptions in this “RB pathway” are part of the life history of many human cancers (for review, see [26]), and alterations of the p16 gene have been found frequently in sporadic and in some familial cancers (for review, see [27]). p16 is probably important in cell senescence, and recent studies have identified a role for p16 in anoikis, cell spreading, and angiogenesis (for review, see [27]). The aim of this retrospective study was to investigate the extent of p27, p21, and p16 protein expression in early SCC, their relation to clinical parameters, and their prognostic significance.

Section snippets

Materials

From January 1987 to December 1993, 242 patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB SCC were treated by radical hysterectomy and bilateral pelvic lymphadenectomy at the Norwegian Radium Hospital. All cervical cancers diagnosed within the hospitals’ catchement area were solely treated at this institution. All patients were preoperatively examined under general anesthesia and tumor diameter was assessed by inspection and palpation. No preoperative screening

Immunohistochemistry

In normal squamous epithelium no p21 or p16 expression was detected, whereas p27 expression was detected in >50% of cells in 9/10 normal epithelia and in 5–50% of cells in the remaining one. Staining was almost exclusively limited to the parabasal and intermediate layers. The staining results in SCC are summarized in Table 1, Table 2. Low (<5% positive nuclei) and high (≥5% positive nuclei) p21 expression were detected in 177/221 (80%) and 44/221 (20%) tumors, respectively (Fig. 1a). Nuclear

Discussion

This study was undertaken to evaluate the prognostic significance of p27, p21, and p16 expression in early stage SCC. p16 expression was correlated with disease-specific survival in univariate but not in multivariate analysis. p27 and p21 expression had no prognostic significance. The traditional clinicopathological variables were of prognostic significance in univariate analysis. In multivariate analysis, only depth of stromal invasion was statistically significant. Metastasis to pelvic lymph

Acknowledgements

We thank Mai Thi Phuong Nguyen, Liv Inger Håseth, Asle Bjåmer, and Ellen Hellesylt for excellent technical assistance.

Supported in part by grants from the Norwegian Cancer Society.

References (56)

  • L.W. Huang et al.

    Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms

    Gynecol Oncol

    (2002)
  • Y.T. Kim et al.

    Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma

    Gynecol Oncol

    (1998)
  • D.S. Bae et al.

    berrant expression of cyclin D1 is associated with poor prognosis in early stage cervical cancer of the uterus

    Gynecol Oncol

    (2001)
  • T. Sano et al.

    Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions

    Am J Pathol

    (1998)
  • J.L. Benedet et al.

    Carcinoma of the cervix uteri

    J Epidemiol Biostat

    (2001)
  • T. Inoue et al.

    Prognostic significance of parametrial extension in patients with cervical carcinoma Stages IB, IIA, and IIBa study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation

    Cancer

    (1984)
  • T. Kamura et al.

    Multivariate analysis of the histopathologic prognostic factors of cervical cancer in patients undergoing radical hysterectomy

    Cancer

    (1992)
  • B.U. Sevin et al.

    Prognostic factors of early stage cervical cancer treated by radical hysterectomy

    Cancer

    (1995)
  • K. Polyak et al.

    p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest

    Genes Dev

    (1994)
  • S. Coats et al.

    Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle

    Science

    (1996)
  • A. Sgambato et al.

    Multiple functions of p27(Kip1) and its alterations in tumor cells: a review

    J Cell Physiol

    (2000)
  • M. Pagano et al.

    Role of the ubiquitin–proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

    Science

    (1995)
  • M. Loda et al.

    Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas

    Nat Med

    (1997)
  • K. Zerfass-Thome et al.

    Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein

    Oncogene

    (1996)
  • I. Zehbe et al.

    Overriding of cyclin-dependent kinase inhibitors by high and low risk human papillomavirus typesevidence for an in vivo role in cervical lesions

    Oncogene

    (1999)
  • C.J. Sherr et al.

    Inhibitors of mammalian G1 cyclin-dependent kinases

    Genes Dev

    (1995)
  • W.S. El Deiry et al.

    WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis

    Cancer Res

    (1994)
  • P. Michieli et al.

    Induction of WAF1/CIP1 by a p53-independent pathway

    Cancer Res

    (1994)
  • Cited by (79)

    • Comparative analysis of p53 and p21 proteins in normal cervix and HPV associated precancerous and cancerous lesions of cervix

      2015, Journal of the Anatomical Society of India
      Citation Excerpt :

      In the normal cell, the level of p21 remains dormant and the protein gets activated only with response to the cellular stress occurred by DNA damage. The expression of this protein has found to be elevated in human cervical cancer.19,20 Although, the studies have also shown the loss of p21 protein during the HPV driven cervical transformation,4 but the exact mechanism still not fully understood.

    View all citing articles on Scopus
    View full text